Jia Liu, Medical oncologist at The Kinghorn Cancer Centre, shared on X:
“The ivonescimab FDA letter raises important questions extending beyond PFS versus OS. Despite approximately 40% of patients being enrolled outside China, 93% of PFS events occurred in Chinese patients.
Geographic representation in trial enrolment does not necessarily translate into geographic representation in the events driving the primary endpoint.
Regional differences in enrolment timing and follow-up maturity may partly explain this imbalance, but the implications for international generalisability remain important.
The lesson? Design for global regulatory approval from the outset.
For emerging oncology drug developers: come and talk to us in Australia starting in Phase I!
We can help build globally relevant evidence from the earliest stages of clinical development.
More About
The FDA concluded that substantial evidence of effectiveness was not established and that the benefit-risk profile did not support approval for ivonescimab added to chemotherapy in patients with EGFR-mutated non-small cell lung cancer (NSCLC).
The main progression-free survival (PFS) results cannot be applied to the US population because 93% of PFS events (257 out of 275) happened in China. As the FDA noted in 2023 and 2025 meetings, the study started only in China – enrolling 60% of patients in 2022 – before expanding to North America and Europe in May 2023.
Adding the drug to chemotherapy showed only a small improvement in median PFS, with no meaningful improvement in overall survival (OS) or overall response rate (ORR).
Additional follow-up analyses for PFS and OS are exploratory only. The OS data is also unreliable across regions because follow-up ended earlier and trial sites closed in China in 2025 compared to North America and Europe.
The small PFS benefit does not justify the added risks. Adding ivonescimab to chemotherapy exposes patients with EGFR-mutated non-small cell lung cancer (NSCLC) to extra serious side effects, including immune-related and VEGF-related toxicities. ”
You can also read: FDA Withholds Ivonescimab Approval in EGFR-Mutant NSCLC: Why HARMONi’s PFS Benefit Was Not Enough
